Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence: Retrospective cohort study of 30 patients

Canadian Family Physician

Volumn 62, Issue 4, 2016, Pages e194-e200

  Dooley, Joe ^a,b   Gerber Finn, Lianne ^a,b   Antone, Irwin ^a,b   Guilfoyle, John ^a,b   Blakelock, Brittany ^b   Balfour Boehm, Jazmyn ^a   Hopman, Wilma M ^c   Jumah, Naana ^a,d   Kelly, Len ^b  

^a NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^b Sioux Lookout Zone and Meno Ya Win Health Centre   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d Thunder Bay Regional Health Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84964522873     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fudala PJ, Bridge TP, Herbert S, Willeford WO, Chiang CN, Jones K, et al. Officebased treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58.
2. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in communitybased primarycare settings. Ann Fam Med 2007;5(2):146-50.
3. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primarycare. J Gen Intern Med 2009;24(2):226-32.
4. Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, et al. Homeversus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat 2010;38(2):153-9. Epub 2009 Oct 3.
5. Doolittle B, Becker W. A case series of buprenorphine/naloxone treatment in a primarycare practice. Subst Abus 2011;32(4):262-5.
6. Poon S, Pupco A, Koren G, Bozzo P. Safety of the newer class of opioid antagonists in pregnancy. Can Fam Physician 2014;60:631-2 (Eng), e348-9 (Fr).
7. Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs 2012;72(6):747-57.
8. Gordon J, Dooley J, Balfour-Boehm J, Rea S, Robinson A, Kelly L. The evolving nature of narcotic use in northwest Ontario. Can J Rural Med 2014;19(4):158-60.
9. Kanate D, Folk D, Cirone S, Rea S, Gordon J, Bocking N, et al. Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence. Evaluating buprenorphine-naloxone substitution therapy in the context of a First Nations healing program. Can Fam Physician 2015;61:160-5.
10. Katt M, Chase C, Samokhvalov A, Argento E, Rehm J, Fischer B. Feasibility and outcomes of a community-based taper-to-low-dose-maintenance Suboxone treatment program for prescription opioid dependence in a remote First Nations community in northern Ontario. J Aborig Health 2012;9(1):52-9.
11. Suboxone (buprenorphine and naloxone) sublingual film. Silver Spring, MD: US Food and Drug Administration; 2014. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm396801.htm. Accessed 2015 Mar 5.
12. Dooley R, Dooley J, Gerber-Finn L, Antone I, Guilfoyle J, Cromarty H, et al. Narcotic tapering in pregnancy using long-acting morphine. An 18-month prospective study in northwestern Ontario. Can Fam Physician 2015;61:e88-95. Available from: www.cfp.ca/content/61/2/e88.full.pdf+html. Accessed 2016 Mar 14.
13. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010;363(24):2320-31.
14. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol 2014;180(7):673-86. Epub 2014 Aug 22.
15. Preston KL, Bigelow GE, Liebsin IA. Effects of sublingually given naloxone in opioid dependent human volunteers. Drug Alcohol Depend 1990;25(1):27-34.
16. Suboxone [product monograph]. Richmond, VA: Reckitt Benckiser Pharmaceuticals; 2014.
17. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92(5):854-8.
18. McCarthy JJ. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus? J Matern Fetal Neonatal Med 2012;25(2):109-12. Epub 2011 Aug 25.
19. Walker R, Cromarty H, Kelly L, St Pierre-Hansen N. Achieving cultural safety in aboriginal health services: implementation of a cross-cultural safety model in a hospital setting. Divers Health Care 2009;6(1):11-22.
20. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict 2013;22(3):252-4.
21. Lund IO, Fischer G, Welle-Strand GK, O'Grady KE, Debelak K, Morrone WR, et al. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse 2013;7:61-74. Epub 2013 Mar 14.
22. Wiegand SL, Stringer EM, Stuebe AM, Hones J, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol 2015;125(2):363-8.
23. Statistics Canada. Health Statistics Division. Births 2009. Catalogue no.84F0210X. Ottawa, ON: Statistics Canada; 2012. Available from: www.statcan.gc.ca/pub/84f0210x/84f0210x2009000-eng.pdf. Accessed 2015 Mar 23.
24. Ordean A, Kahan M, Graves L, Abrahams R, Kim T. Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a Canadian multisite cohort study. J Obstet Gynaecol Can 2015;37(3):252-7.
25. Kelly L, Dooley J, Gerber-Finn L, Antone I, Dooley R, Muileboom J, et al. Incidence of narcotic abuse during pregnancy in northwestern Ontario. Three-year prospective study of an increasing challenge. Can Fam Physician 2014;60:e493-8. Available from: www.cfp.ca/content/60/10/e493.full.pdf+html. Accessed 2016 Mar 14.
26. Kelly L, Cromarty H, Minty B, Morgan A, Madden S, Hopman W, et al. Narcoticexposed neonates in a First Nations population in northwestern Ontario. Incidence and implications. Can Fam Physician 2011;57:e441-7. Available from: www.cfp.ca/content/57/11/e441.long. Accessed 2016 Mar 14.